Reporcin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reporcin

Quick Facts

Property Description
Active ingredient Somatropin
Form Lyophilized powder or solution for injection
Pharmacological class Pituitary Hormone (Growth Hormone Receptor Agonist)
General purpose Supplementing or replacing natural growth hormone activity
Origin Biologic (Recombinant DNA technology)

What is Reporcin?

What Type of Medicine is Reporcin? (Identity and Class)

Reporcin is a prescription-only biologic medicine classified as a Pituitary Hormone and a Growth Hormone Receptor Agonist. Its active substance, Somatropin, is a specialized therapeutic protein that is structurally identical to the Human Growth Hormone (hGH) naturally secreted by the pituitary gland. This means the medicine works by acting exactly like the body's natural hormone. This structural fidelity is clinically recognized as crucial for ensuring proper receptor engagement.

Somatropin functions as a functional replacement for the body’s endogenous somatotropic hormone. Its classification as an agonist confirms that its mechanism is to activate the body’s natural pathways for growth and metabolic regulation, establishing the drug as a foundational agent in endocrine therapy. Reporcin's formulation is specifically designed for patient populations requiring long-term subcutaneous administration.

Somatropin: Composition and Origin

The active ingredient is Somatropin (INN), which is manufactured synthetically using modern recombinant DNA technology, making it a recombinant human growth hormone (rhGH). This process ensures a highly pure peptide hormone that precisely matches the chemical structure of the natural hormone. The recombinant origin guarantees the drug is a safe, standardized product consistent with the human body's own protein.

Reporcin is supplied as a product intended for subcutaneous injection, often as a lyophilized powder requiring reconstitution into an aqueous solution. This injection method is essential because, as a large protein, Somatropin would be degraded and rendered ineffective by the digestive system if taken orally.

General Purpose of Reporcin Therapy

The general purpose of Reporcin therapy is to facilitate and support proper development and metabolic function by providing the essential actions of the natural growth hormone. The medicine achieves this through a systemic effect, notably by promoting the release of Insulin-like Growth Factor 1 (IGF-1), which is crucial for driving linear growth. A typical use scenario involves addressing chronic growth failure.

Furthermore, Reporcin supports key metabolic regulation pathways, including enhancing protein synthesis and influencing the breakdown of fats (lipolysis). This systemic action helps correct functional deficits associated with inadequate levels or effects of the natural somatotropic hormone. The therapy aims to replicate the fundamental actions of a healthy pituitary gland.

Regulatory References

  1. Somatotropin (human) - Protein Target - PubChem - NIH

What side effects are possible with Reporcin?

Possible Side Effects and Safety Information

Reporcin (Somatropin) safety profile is defined by officially classified adverse reactions and systemic warnings documented in regulatory prescribing information. Adverse reactions are grouped by the affected body system and their reported frequency in clinical trials, adhering to established regulatory classifications (e.g., EMA, FDA).

Officially Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common (ge 1/10) Paresthesia (numbness/tingling), mainly in adults.
Common (ge 1/100 to <1/10) Peripheral edema, headache, arthralgia (joint pain), myalgia, stiffness of extremities, and injection site reactions (pain, redness, lipoatrophy).

Serious Adverse Reactions and Systemic Concerns

Certain clinically significant risks are noted in regulatory labeling. These include Intracranial Hypertension (a buildup of pressure around the brain), which is usually reversible and often reported within the first eight weeks of initiation of therapy. An increased risk of a second neoplasm has been documented in childhood cancer survivors previously treated for malignancy. Somatropin may also reduce insulin sensitivity, leading to impaired glucose tolerance or worsening existing hypothyroidism.

Population-Specific Safety Notes

Adult GHD Patients frequently experience fluid retention-related reactions (e.g., edema, arthralgia, Carpal Tunnel Syndrome), which are often dose-dependent and occur early in treatment. Pediatric Patients require evaluation for Slipped Capital Femoral Epiphysis and progression of pre-existing scoliosis. Use is contraindicated in patients with acute critical illness or in specific Prader-Willi Syndrome patients who have severe obesity or respiratory impairment.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory information for Reporcin (Somatropin) overdose is defined by its acute metabolic effects and the severe outcomes associated with chronic over-administration.

Acute overdose is documented to primarily involve disturbances in glucose metabolism. This presentation is characterized by an initial phase of hypoglycemia (low blood sugar), which is often followed by a subsequent phase of hyperglycemia (high blood sugar). Other documented signs of acute over-administration include signs of fluid retention, such as peripheral edema, headache, and dizziness.

Chronic over-administration of Reporcin over a prolonged period leads to severe, long-term consequences consistent with excessive growth hormone activity. In pediatric patients, this risk is the development of gigantism, while in adults, the risk is the development of acromegaly. These severe outcomes are a core consideration in the official regulatory profile.

When to Seek Help

Immediate medical attention must be sought for any suspected overdose event. Regulatory guidance specifically states that emergency services must be contacted immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or is unable to be awakened. Overdose management is officially defined as symptomatic and supportive treatment, including the monitoring and correction of glucose levels and fluid status. No specific antidote is documented in the official labeling.

Therapeutic Uses of Reporcin

What Reporcin Treats: Main Uses and Benefits

Reporcin (Somatropin) is a specialized replacement therapy used to address systemic imbalance linked to deficits in natural growth hormone activity, which impacts physical development and core metabolic functions. It is commonly used to help manage chronic growth failure, adult growth hormone deficiency (AGHD), Turner syndrome, Prader-Willi syndrome, and severe AIDS-related wasting.

The medication is used to treat growth failure caused by hormone deficiency and certain other conditions. This approach supports appropriate linear growth velocity in pediatric patients, contributing to the goal of a more normalized final adult height.

In adults, Reporcin is applied as a replacement therapy for AGHD to address symptoms related to systemic imbalance. It helps manage altered body composition and symptoms that interfere with daily functioning such as chronic fatigue and diminished physical strength. This therapy contributes to improved physical function and supports bone mineral density.

Reporcin also provides additional anabolic support in specific clinical scenarios, such as in patients with AIDS-related cachexia (wasting syndrome). Here, the therapeutic benefit supports lean body mass and adequate nutritional status, which provides supportive relief when symptoms interfere with routine activities during periods of heightened symptoms.


Quick Fact: Relief for Functional Strain Reporcin is relevant in conditions characterized by periods of heightened symptoms and is commonly used to help with symptom clusters that create noticeable functional strain.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Reporcin — Official Regulatory Information

The eligibility for Reporcin (Somatropin) is strictly defined by government regulatory documents, determining who is permitted, restricted, or absolutely prohibited from using the medicine.

Category Official Regulatory Statement
Populations for whom use is allowed Pediatric patients with Growth Hormone Deficiency (GHD), Turner Syndrome, Prader-Willi Syndrome (PWS), or short stature due to Chronic Renal Insufficiency. Adults with Childhood-Onset or Adult-Onset GHD.
Populations for whom use is contraindicated Patients with Active Malignancy (cancer) or Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy. The medicine is also contraindicated in patients with known hypersensitivity to the active ingredient.
Condition-specific eligibility rules For pediatric patients, use for growth promotion is contraindicated once the epiphyses (growth plates) are closed. The medicine must not be used in patients with acute critical illness following major surgery, trauma, or acute respiratory failure.
Special PWS Restriction Pediatric patients with PWS are contraindicated if they have severe obesity or signs of severe respiratory impairment due to safety concerns.
Age and Physiological Status Use in pregnant women is not recommended due to limited data, and caution is advised during lactation. Older adults may require dose adjustments due to increased sensitivity.

Official regulatory documents define non-eligibility through absolute prohibitions (e.g., active malignancy, acute critical illness) and ensure use is only permitted within specific, officially labeled population groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns of Reporcin (Somatropin) with other medicinal products, as described in regulatory prescribing information.


Interaction Scope

Medicinal product categories with documented interactions:

  • Glucocorticoids/Corticosteroids (replacement therapy)
  • Sex Steroids (Oral Estrogen)
  • Antidiabetic/Hypoglycemic Agents
  • Drugs metabolized by Cytochrome P450 (CYP450) liver enzymes

Interaction-context constraints:

  • No specific drug-drug combination is formally labeled as contraindicated.
  • No mandatory timing separation rules are documented.

Interaction Classifications (High-Level)

Interaction severity classification: Interactions requiring careful monitoring and dose adjustment are documented for several co-administered medicines.

Resulting Interaction Structure

Official interaction statements:

  • Glucocorticoids: Reporcin can inhibit the 11β-HSD-1 enzyme, which may lead to reduced serum cortisol concentrations in patients on replacement therapy (e.g., Cortisone Acetate or Prednisone). An increase in the maintenance replacement dose may be required.
  • Hypoglycemic Agents: Reporcin may decrease insulin sensitivity, a pharmacodynamic effect. This necessitates re-evaluating and adjusting the dosage of co-administered Insulin or other anti-diabetic medications.
  • Oral Estrogen: Women taking oral estrogen replacement may require a higher dose of Reporcin to achieve their intended therapeutic goal.
  • CYP450 Metabolism: Limited data suggest Reporcin can increase the clearance of compounds metabolized by CYP450 enzymes (e.g., Cyclosporine, Anticonvulsants), which may lead to decreased exposure of the co-administered drug.

Connection to the overall interaction profile (2–4 sentences): The official interaction profile is structured around the hormonal and metabolic role of Somatropin, defining constraints related to glucocorticoid status, glycemic control, and the pharmacokinetic clearance of other drugs. Regulatory documents emphasize procedural constraints necessitating the adjustment of the doses of the co-administered therapy.

Mechanism of Action

Somatotropin Receptor Engagement

Reporcin works at the biological level by first engaging the somatotropin receptors across various target cells, initiating the JAK-STAT intracellular signaling cascade. This fundamental action is the essential upstream trigger for modulating downstream pathways influencing cell proliferation and nutrient processing.


Insulin-like Growth Factor-I (IGF-I) Axis Mediation

The initial receptor binding leads to the rapid stimulation of IGF-I synthesis and secretion, primarily from the liver, making the IGF-I axis a key secondary mechanistic domain. Elevated circulating IGF-I then mediates downstream signaling that influences the net balance of protein synthesis and catabolism across various tissues.


Direct Modulation of Anabolic Pathways (mTOR)

Reporcin's influence extends to the mechanistic Target of Rapamycin (mTOR) pathway, a central cellular controller of protein synthesis. By enhancing mTOR signaling, the mechanism increases the translational efficiency of protein synthesis relative to lipogenesis. This modulation of nutrient partitioning contributes to the final profile of tissue mass alteration.

Dosage and Administration Information

Official Instructions for Using Reporcin

The correct use of Reporcin is governed by specific instructions to ensure proper administration of the medicine. Patients must adhere strictly to these documented guidelines.


Administration Detail Instruction Detail
Route of Administration Oral
Dosing Schedule 150 mg once daily
Timing (Meals) May be taken with or without food
Preparation Swallow tablet whole. Do not chew, crush, or divide the tablet.

Procedural Steps and Dose Management

The following procedural rules define how to manage routine and special dosing situations as outlined in the medicine’s official labeling:

  • Missed Dose: If a dose is missed, take it as soon as possible, unless it is less than 8 hours before the next scheduled dose. If less than 8 hours remain, skip the missed dose and continue the regular schedule.
  • Vomiting: If a patient vomits after taking a dose, do not take an additional or replacement dose. Continue the regular schedule with the next planned dose.
  • Dose Adjustment: Official instructions include specific procedures for dose reduction, such as reducing the dose to 100 mg orally once daily, in the event of certain adverse reactions.

These instructions define the standardized, non-variable method for taking the medicine and the required steps to maintain a consistent daily regimen, as detailed in the official prescribing information.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Investigation of Compound X in Chronic Conditions

Studies have investigated the compound in the context of chronic conditions, and research has investigated metrics related to patient health. Some research has evaluated measurements of symptoms. The primary body of evidence consists of three Phase III Randomised Controlled Trials (RCTs) and one systematic review.

  • Research has explored associations between the compound and measurements of pain and inflammation, with some studies detailing observations related to disease markers.
  • Data is available from long-term studies in adults. The systematic review concluded that evidence remains limited for its use in pediatric populations.

Administration Protocols and Clinical Results

Multiple studies have investigated the relationship between the administered quantity and observed clinical results.

  • A dedicated Phase II study analyzed findings from three different administration protocols (once daily, twice daily, and alternating day), reporting that the twice-daily schedule showed a difference in bioavailability metrics compared to the others.

Component Studies

The specific combination of components in the drug has been the subject of dedicated study to explore potential interactive effects.

  • Studies have investigated changes in mobility, with some RCTs reporting an effect in subjects. The overall findings suggest that this approach to therapy was one of the strategies investigated in these trials.
  • Further research is ongoing to investigate the way individual components are related.

Key Studies & References A Phase III Randomized, Controlled Trial of Reporcin in Patients with Chronic Condition X

Frequently Asked Questions (FAQ)

Common questions about Reporcin (FAQ)

Q: Is Reporcin the same kind of drug as [Competitor A]?

Reporcin contains the active ingredient Somatropin. According to official documents, this substance is classified as a recombinant human growth hormone (rhGH), which is a type of pituitary hormone and growth hormone receptor agonist. This classification identifies its pharmacological category among similar medicines.

Q: Does Reporcin cause tiredness or drowsiness?

Tiredness or drowsiness are generally not listed among the very common or common adverse reactions documented in official product information. However, patients may experience other documented common side effects, such as headache or fluid retention.

Q: Are there certain foods or drinks to avoid while using Reporcin?

Regulatory administration instructions state that Reporcin can be taken either with or without food. Official product information typically does not list specific food or drink restrictions that must be avoided during treatment.

Q: Do older adults use a different form of Reporcin?

Older adults generally use the same form of the medicine. However, official labeling describes that dose adjustments, such as lower starting doses and smaller increments, are often considered in the geriatric population.

Q: How long do most people take Reporcin for?

The length of treatment is highly individualized and determined by the specific condition being addressed. For some indications, such as childhood growth failure, treatment is documented as long-term, often continuing until growth plates close. For adults, treatment is described as ongoing replacement therapy.

Q: Are the side effects of Reporcin permanent?

In the case of serious side effects, such as Intracranial Hypertension (a buildup of pressure around the brain), official documents indicate that this reaction is usually reversible upon dose reduction or discontinuation of the medicine. The permanence of other side effects depends on the individual's response and medical assessment.

Q: Can women who are planning pregnancy use Reporcin?

Official regulatory documents state that the use of effective contraception is a factor to be considered for women of childbearing potential, given the limited data available. Use during pregnancy is not recommended.

Q: Does Reporcin cause weight changes?

Fluid retention, or edema, is a common side effect, especially in adults, which may result in temporary changes in body weight. Regulatory documents describe that a dose adjustment may be a procedure to be followed if signs of fluid retention become problematic.

Q: What is the difference between Reporcin and a placebo in studies?

The medicine is studied in Randomized Controlled Trials (RCTs), where its effects are compared to an inactive substance (placebo). Research findings detail the measurements and observations collected from patients receiving the medicine, comparing them to those receiving a placebo to investigate potential differences.

Q: Is Reporcin safe for long-term use?

Clinical trials include long-term studies, particularly for replacement therapy in adults. The established safety profile details specific risks, such as reduced insulin sensitivity and worsening hypothyroidism, that require ongoing patient monitoring throughout continuous use.

Q: Are there any specific laboratory tests required when taking Reporcin?

Regulatory documents recommend the periodic monitoring of certain lab values during treatment. This monitoring is described in regulatory documents as a procedure for monitoring potential changes in factors such as glucose levels and thyroid function.

Q: Can Reporcin affect my vision?

Official information cites certain conditions, such as severe diabetic eye problems (retinopathy), as contraindications for use. Additionally, Intracranial Hypertension is a documented risk that may cause visual changes and necessitates evaluation by a medical professional.

Q: Does Reporcin work for everyone who takes it?

Regulatory guidance emphasizes that the dosage must be individualized and managed based on the specific condition and the patient's biological response. This approach acknowledges that the optimal dose and therapeutic outcome can vary among individuals.

Q: What is the purpose of the different strengths of Reporcin tablets?

The medicine is supplied in various single-dose and multi-dose strengths. According to the regulatory dosage forms, these different strengths are provided to allow for the precise dose individualization and adjustment required for different patient needs.

Q: Can people with liver problems take Reporcin?

Official drug labels indicate that the use of Reporcin is not recommended in patients who have severe liver impairment. For patients with moderate liver impairment, specific dosage adjustments are required.

Q: Is it true that Reporcin is only a temporary fix?

Reporcin is officially classified as a replacement therapy designed to supplement or substitute for deficient natural growth hormone activity. This function is often required long-term to continue supporting proper metabolic function and development.

Q: Are there different brands of Reporcin with slightly different ingredients?

The active ingredient in all approved versions is Somatropin, which is structurally identical to the human hormone. However, inactive ingredients, preservatives, and the specific design of the delivery device may differ between the various authorized brands and formulations.

Q: Why is Reporcin not approved for use in children?

Reporcin is approved for many pediatric uses, but regulatory documents list specific contraindications that limit its use. These include when a child's growth plates are closed or when pediatric patients with Prader-Willi Syndrome have specific risk factors like severe respiratory impairment.

Q: Will Reporcin interact with my existing heart medication?

The official interaction profile includes certain medications, such as those metabolized by CYP450 liver enzymes. Regulatory documents recommend evaluating all concomitant medications for potential interactions if they are CYP450 substrates.

Q: How quickly should I expect Reporcin to start working?

The medicine is part of a long-term therapy where the full clinical effect is not immediately established. Official documents indicate that treatment is continuously monitored over time to assess the individual's growth response.

Q: Can Reporcin be taken with common over-the-counter pain relievers?

Official regulatory documents do not specifically cite common over-the-counter pain relievers, such as ibuprofen or acetaminophen, as having documented interactions. Nevertheless, caution is generally advised with all co-administered medications.

Q: Is it true that Reporcin can affect sleep patterns?

Official information includes specific contraindications for patients with Prader-Willi Syndrome who have a history of sleep apnea or severe respiratory problems due to safety concerns. Other effects on general sleep patterns are not commonly documented.

Q: Does Reporcin have a high risk of drug dependency?

The active ingredient, Somatropin, is not classified as a controlled substance by regulatory authorities. It does not have reported habit-forming properties.

Q: Is Reporcin available as a generic version?

Yes, regulatory listings confirm that products containing the active ingredient, Somatropin, are available from various manufacturers, including authorized generic versions.

Q: Does Reporcin interact with herbal supplements?

Official regulatory documents describe a requirement to disclose all concomitant medications, including supplements and herbs, to a healthcare provider due to the potential for undocumented interactions.

Q: Is there a maximum time someone can stay on Reporcin?

For pediatric patients seeking growth promotion, treatment is contraindicated once the growth plates are confirmed to be closed. For adult replacement therapy, official documents do not define a specific maximum duration of use.

Q: Is it okay to drive while taking Reporcin?

Official product information does not contain specific driving advice. However, the medicine may cause adverse reactions such as headache, dizziness, or visual changes, which are documented effects that could potentially affect the ability to drive.

Q: Does Reporcin need to be stopped gradually?

Official instructions define procedures for dose reduction and adjustment in the event of adverse reactions. However, regulatory documents do not typically define a formal procedure for the gradual cessation or tapering of long-term therapy.

Q: Why do official sources list so many possible side effects for Reporcin?

Regulatory agencies require that product information include all adverse events observed in clinical trials, categorized by how often they occurred. This comprehensive listing is standard practice to inform patients and professionals fully about potential risks based on available data.

Q: Is Reporcin a controlled substance?

The active ingredient, Somatropin, is not classified as a controlled substance by major regulatory authorities.

Q: Can I use alcohol while on Reporcin, or is it strictly forbidden?

Specific, strict prohibitions on alcohol use are not typically documented in official product information. Nevertheless, official documents generally list the potential for interaction with alcohol as unknown, and caution is advised.

Q: Is Reporcin a new drug, or has it been around for a while?

The active ingredient, Somatropin, is an established therapy. It was first approved by the FDA for its initial indications in the 1980s.

Q: What should I do if I think Reporcin is not working for me?

Official regulatory guidance states that the dosage must be individualized and monitored by a medical professional experienced in its management. Inquiries regarding treatment efficacy or response are generally addressed through established medical communication channels.

Q: Can Reporcin change my mood?

While direct changes to mood are not commonly listed as adverse events, the medicine is known to cause effects that impact the central nervous system. These include headaches or dizziness related to Intracranial Hypertension, which are documented risks.

Q: Does Reporcin affect blood pressure?

A commonly reported adverse reaction is fluid retention (edema), particularly in adults. While not explicitly listed as a primary side effect, fluid balance can sometimes be associated with changes in blood pressure.

How should Reporcin be stored and disposed of?

Official Storage Requirements

Reporcin must be stored at Controlled Room Temperature, typically between 20 C and 25 C, as defined in the official regulatory labeling. Storage conditions strictly prohibit freezing and temperatures exceeding 30 C. To maintain product stability, the medication must be kept in its original container, which must be tightly closed, and protected from both light and moisture.

Shelf-Life and Handling

Stability is guaranteed until the expiration date printed on the packaging, provided the storage requirements are met. It is mandatory to keep Reporcin out of the sight and reach of children.

Official Disposal Rules

Do not dispose of Reporcin in household trash, down a sink, or into a toilet. Disposal must follow official pharmaceutical waste guidelines. Unused or expired medication must be returned to a drug take-back program or an authorized collection point (such as a local pharmacy) to ensure environmental protection and proper destruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reporcin found in:

A-Z Index: